Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TBPH

Theravance Biopharma Inc

Nov 05 • 04:00PM ET

14.95

+0.20 1.36 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD BMRN INCY IONS NBIX ALNY MDGL SRPT

| Held by: VTI IWM VXF IBB IWO SCHA VTWO DFAS JSML DFAC

Scroll to Statements

Index	RUT	P/E	63.92	EPS (ttm)	0.23	Insider Own	7.21%	Shs Outstand	50.36M	Perf Week	5.50%
Market Cap	752.90M	Forward P/E	50.56	EPS next Y	0.30	Insider Trans	-0.93%	Shs Float	46.73M	Perf Month	4.18%
Enterprise Value	460.56M	PEG	0.87	EPS next Q	-0.13	Inst Own	93.62%	Short Float	10.64%	Perf Quarter	33.36%
Income	13.03M	P/S	9.75	EPS this Y	230.13%	Inst Trans	4.63%	Short Ratio	11.95	Perf Half Y	49.65%
Sales	77.20M	P/B	3.35	EPS next Y	-80.24%	ROA	3.31%	Short Interest	4.97M	Perf YTD	58.87%
Book/sh	4.46	P/C	2.22	EPS next 5Y	73.26%	ROE	6.23%	52W High	15.34 -2.51%	Perf Year	80.56%
Cash/sh	6.73	P/FCF	3.08	EPS past 3/5Y	26.18% 22.95%	ROIC	5.00%	52W Low	7.90 89.24%	Perf 3Y	49.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.19% -2.59%	Gross Margin	92.68%	Volatility	4.26% 3.48%	Perf 5Y	-22.42%
Dividend TTM	-	EV/Sales	5.97	EPS Y/Y TTM	126.61%	Oper. Margin	-49.14%	ATR (14)	0.53	Perf 10Y	3.75%
Dividend Ex-Date	-	Quick Ratio	6.70	Sales Y/Y TTM	24.49%	Profit Margin	16.88%	RSI (14)	61.31	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.70	EPS Q/Q	418.79%	SMA20	4.67%	Beta	0.18	Target Price	20.00
Payout	-	Debt/Eq	0.21	Sales Q/Q	83.75%	SMA50	5.55%	Rel Volume	1.17	Prev Close	14.75
Employees	97	LT Debt/Eq	0.16	Earnings	Nov 10 AMC	SMA200	33.78%	Avg Volume	416.11K	Price	14.95
IPO	May 16, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.50% 1.00%	Trades		Volume	488,794	Change	1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-25	Initiated	B. Riley Securities	Buy	$28
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform	$15 → $10
Apr-12-24	Initiated	BTIG Research	Buy	$21
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform	$12
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral	$12
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight	$7
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight	$27 → $14
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform	$42 → $14
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$32
Jul-07-20	Initiated	JP Morgan	Overweight	$29
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight	$30
May-13-20	Initiated	Cowen	Outperform	$42
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral	$22 → $18
Oct-29-19	Initiated	H.C. Wainwright	Buy	$25
Mar-29-18	Resumed	Piper Jaffray	Overweight	$45
Aug-17-17	Initiated	Evercore ISI	Outperform	$45
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$55
May-11-17	Reiterated	Needham	Buy	$40 → $45

Show Previous Ratings

Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Oct-29-25 06:00AM	Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System (PR Newswire)
Oct-27-25 06:00AM	Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire)
Oct-16-25 08:05AM	Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy (Business Wire)
Oct-14-25 06:00AM	Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting (PR Newswire)
11:30AM	Loading…
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-25 06:00AM	Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-25-25 06:00AM	Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy (PR Newswire)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:14AM	Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... (GuruFocus.com)
Aug-12-25 05:25PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Theravance Bio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:29AM	Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 08:25AM	Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 (Zacks)
06:00AM	Loading…
Jul-28-25 06:00AM	Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-23-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 08:59AM	Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma (Insider Monkey)
Jun-27-25 07:36AM	Viatris gains China approval for Yupelri to treat COPD (Pharmaceutical Technology)
Jun-26-25 06:00AM	Theravance Biopharma Announces Approval of YUPELRI (revefenacin) by China's NMPA (PR Newswire)
Jun-03-25 11:53AM	TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises (Zacks)
Jun-02-25 06:00AM	Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million (PR Newswire) +21.72%
May-13-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
May-09-25 12:39PM	Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.29%
12:00PM	Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress (PR Newswire)
03:47AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
May-08-25 06:05PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
10:52AM	Loading…
May-07-25 10:52AM	Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-06-25 05:30PM	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
Apr-28-25 06:00AM	Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress (PR Newswire)
Apr-24-25 06:00AM	Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
Apr-07-25 03:55PM	Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting (PR Newswire)
Mar-31-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Mar-28-25 11:30AM	Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? (Zacks)
Mar-27-25 06:00AM	Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology (PR Newswire)
Feb-27-25 02:26AM	Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-26-25 05:15PM	Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-25-25 10:55AM	Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result (GuruFocus.com)
Feb-20-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-12-25 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (PR Newswire)
Feb-05-25 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jan-27-25 03:57AM	Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? (Zacks) -7.64%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-19-24 08:00AM	Government Contractor KBR, Recently Hit by DOGE Fears, Draws Activist Investor (The Wall Street Journal)
Dec-17-24 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference (PR Newswire)
Dec-12-24 11:30AM	Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-20-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Nov-13-24 02:22AM	Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.64%
Nov-12-24 06:05PM	Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value (PR Newswire)
Nov-11-24 07:16AM	What To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings (GuruFocus.com)
Oct-24-24 06:00AM	Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 (PR Newswire)
Oct-18-24 09:00AM	Theravance Announces Publication of YUPELRI (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease (PR Newswire)
Sep-10-24 11:01AM	Seth Klarman's Complete Exit from Theravance Biopharma Inc (GuruFocus.com)
Sep-04-24 11:30AM	Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-27-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Aug-14-24 05:03PM	Seth Klarman's Strategic Reduction in Theravance Biopharma Inc (GuruFocus.com)
Aug-06-24 10:56AM	Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -18.35%
Aug-05-24 06:00PM	Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Jul-25-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Jul-22-24 06:00AM	Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 (PR Newswire) +7.00%
Jun-26-24 11:28AM	Here's Why You May Invest in Theravance (TBPH) Stock Now (Zacks)
Jun-21-24 09:55AM	Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know (Zacks)
Jun-12-24 11:30AM	Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-15-24 03:56PM	Klarman's Baupost Group Buys Stake in SoundHound, Cuts Position in Warner Bros Discovery (Investopedia)
May-14-24 12:06PM	Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates (Zacks)
May-13-24 08:54PM	TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:25PM	Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours (MT Newswires)
05:15PM	Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-09-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Apr-29-24 06:00AM	Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace)
07:47AM	Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength? (Zacks)
Apr-10-24 06:00AM	Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 (PR Newswire)
Mar-27-24 11:30AM	Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? (Zacks)
Mar-12-24 03:59PM	Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics (InvestorPlace)
Feb-28-24 10:35AM	Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:47AM	Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates (Zacks)
Feb-26-24 05:25PM	Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:39PM	Theravance Bio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-22-24 06:00AM	Theravance Biopharma to Participate in an Upcoming Investor Conference (PR Newswire)
Feb-14-24 06:00AM	Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 (PR Newswire)
Jan-12-24 09:35AM	Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround (Zacks)
Jan-05-24 06:00AM	Theravance Biopharma Announces Results from the Phase 4 YUPELRI PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire) -9.98%
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Dec-21-23 05:00PM	Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors (PR Newswire)
Dec-18-23 06:00AM	Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference (PR Newswire)
Dec-07-23 11:30AM	Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-22-23 09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-16-23 06:00AM	Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System (PR Newswire)
Nov-15-23 06:00AM	Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire)
Nov-13-23 08:00AM	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 14 '25	Sale	11.39	10,000	113,870	326,918	Jul 16 06:01 PM
RHONDA FARNUM	Officer	Jul 14 '25	Proposed Sale	11.39	10,000	113,869		Jul 14 04:03 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 02 '25	Sale	11.00	24,000	264,000	336,918	Jun 04 06:04 PM
RHONDA FARNUM	Officer	Jun 02 '25	Proposed Sale	11.00	24,000	264,000		Jun 02 04:25 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Apr 21 '25	Sale	9.00	4,000	36,000	370,038	Apr 23 06:00 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jan 21 '25	Sale	9.00	4,000	36,000	309,565	Jan 23 06:05 PM
RHONDA FARNUM	Officer	Jan 21 '25	Proposed Sale	9.00	4,000	36,000		Jan 21 04:03 PM
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Nov 11 '24	Sale	9.00	4,000	36,000	322,743	Nov 13 08:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TBPH

Theravance Biopharma Inc

Upgrade your FINVIZ experience